FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA 001A	APPLICATION NO 09/492,709
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Zyskind et al	
		FILING DATE January 27, 2000	GROUP 1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
AM	1	US 2002/0058260 A1	05 16 02	Zyskind et al	435	6	RECEIVED
							AUG 2 2 2002
							TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

S DOCS JEH JEH-1357 DOC 072902

EXAMINER Ardin Marsden	DATE CONSIDERED 12-20-02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001A	APPLICATION NO. 09/492,709
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Zyskind, et al.	**RECEIVED**
		FILING DATE January 27, 2000	GROUP 1631	OCT 1 1 2002 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
ΛM	1	5,874,281	02/23/99	Dattagupta, et al.	435	238	
ΛM	2	5,874,567	02/23/99	Smith	536	24.5	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AM	3	WO 95/29254	11/02/95	PCT, Atkins et al	—			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

S:\DOCS\DOH\DOH-7082.DOC:dmb
100402

EXAMINER	Ardin Marschel	DATE CONSIDERED	12-20-02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001A	APPLICATION NO 09/492,709
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Zyskind, et al.	
		FILING DATE January 27, 2000	GROUP 1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
∧M	1	6,228,579 B1	05/08/01	Zyskind, et al.	435	6	
∧M	2	6,228,588 B1	05/08/01	Benton, et al.	435	6	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
∧M	3	Good, et al. 1998. Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA. *Proc. Natl. Acad. Sci. USA*, 95:2073-2076

S:\DOCS\DOH\DOH-6819.DOC:dmb
062402

EXAMINER Ardin Mansely	DATE CONSIDERED 12·20·02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001A	APPLICATION NO 09/492,709
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Zyskind, et al	
		FILING DATE January 27, 2000	GROUP 1631

Stamp: MAY 07 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
					364	499	
AM	1	5,353,236	10/04/94	Subbiah			
AM	2	5,869,604	02/09/99	Rousseau, et al	530	344	
AM	3	6,077,682	06/20/00	Inouye, et al	435	15	
AM	4	6,156,526	12/05/00	Boriack-Sjodin, et al	435	18	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
AM	5	WO 99/13893	03/25/99	PCT, Nielsen et al				

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
AM	6	Appelt, K. 1993. Crystal structures of HIV-1 protease-inhibitor complexes. *Perspectives in Drug Discovery and Design*, 1:23-48
	7	Bagby, et al. 1994. Unusual helix-containing Greek keys in development-specific Ca^{2+}-binding protein S. ^{1}H, ^{15}N, and ^{13}C assignments and secondary structure determined with the use of multidimensional double and triple resonance heteronuclear NMR spectroscopy. *Biochemistry*, 33:2409-2421
	8	Bagby, et al. 1995. Solution structure of the C-terminal core domain of human TFIIB. Similarity to Cyclin A and interaction with TATA-binding protein. *Cell*, 82:857-867
	9	Balbes, et al. 1994. "A perspective of modern methods in computer-aided drug design." In Lipkowitz, et al., Eds. Reviews in Computational Chemistry V. Chap. 7, pp. 337-379. New York: VCH Publishers
	10	Brunschwig, et al. 1992. A two-component T7 system for the overexpression of genes in *Pseudomonas aeruginosa*. *Gene*, 111:35-41
	11	Bugg, et al. 1993. Drugs by design: Structure-based design, an innovative approach to developing drugs, has recently spawned many promising therapeutic agents, including several now in human trials for treating AIDS, cancer and other diseases. *Scientific American*, Dec.:92-98.
	12	Clore, et al. 1987. Three-dimensional structure of potato carboxypeptidase inhibitor in solution. A study using nuclear magnetic resonance, distance geometry, and restrained molecular dynamics. *Biochemistry*, 26:8012-8023.
	13	Crosa, et al. 1973. Molecular relationships among the Salmonelleae. *J. Bacteriol*, 115(1):307-315.
	14	Cwirla, et al. 1990. Peptides on phage: A vast library of peptides for identifying ligands. *Proc. Natl. Acad. Sci. USA*, 87:6378-6382
	15	Devlin, et al. 1990. Random peptide libraries: A source of specific protein binding molecules. *Science*, 249:404-406
	16	Edwards, B.H. 1999. *Salmonella* and *Shigella* species. *Clinics Lab. Med.*, 19(3):469-487.

EXAMINER	Aidan Marschel	DATE CONSIDERED	12-20-02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO ELITRA 001A	APPLICATION NO 09/492,709
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Zyskind, et al	
	FILING DATE January 27, 2000	GROUP 1631

MAY 07 2002

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
JM	17	Erickson, J. W. 1993. Design and structure of symmetry-based inhibitors of HIV-1 protease. *Perspectives in Drug Discovery and Design*, 1:109-128
	18	Good, et al. 1998. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. *Nature Biotechnology*, 16:355-358.
	19	Huycke, et al. 1998. Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. *Emerging Infectious Diseases*, 4(2):239-249.
	20	Israelsen, et al. 1995. Cloning and partial characterization of regulated promoters from *Lactococcus lactis* Tn917-lacZ integrants with the new promoter probe vector, pAK80. *Applied and Environmental Microbiology*, 61(7):2540-2547.
	21	Kreiswirth, et al. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. *Nature*, 305:709-712
	22	Lam, et al. 1994. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. *Science*. 263:380-384
	23	Marrone, et al. 2000. Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: A virtual screening approach. *Perspectives in Drug Discovery and Design*, 20:209-230
	24	Mestres, et al. 2000. Similarity *versus* docking in 3D virtual screening. *Perspectives in Drug Discovery and Design*, 20:191-207
	25	Mojumdar, et al. 1988. Characterization of the tetracycline resistance gene of plasmid pT181 of *Staphylococcus aureus*. *J. Bacteriology*, 170(12):5522-5528
	26	Moszer, et al. 1995. *SubtiList*: A relational database for the *Bacillus subtilis* genome. *Microbiology*, 141:261-268
	27	Moszer, I. 1998. The complete genome of *Bacillus subtilis*: From sequence annotation to data management and analysis. *FEBS Letters*, 430:28-36
	28	Neidhardt, F. C. (Ed.) 1996. *Escherichia coli* and *Salmonella*: Cellular and molecular biology. 2nd Ed., Vol. 2, pp. 2269-2271. Washington D.C.: ASM Press
	29	Schnappinger, et al. 1995. Extracellular expression of native human anti-lysozyme fragments in *Staphylococcus carnosus*. *FEMS Microbiol. Let.* 129:121-127.
	30	Scott, et al. 1990. Searching for peptide ligands with an epitope library. *Science*, 249:386-390.
	31	Shuker, et al. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. *Science*, 274:1531-1534.
	32	Suh, et al. 1995. Genetic and transcriptional organization of the *Bacillus subtilis* spc-alpha region. Database accession no. L47971 (ID: BSRPLP), XP002190118.
	33	Suh, et al. 1996. Genetic and transcriptional organization of the *Bacillus subtilis* spc-alpha region. *Gene*, 169:17-23
	34	Tatusov, et al. 2000. The COG database: A tool for genome-scale analysis of protein functions and evolution. *Nucleic Acids Research*, 28(1):33-36
	35	Van Delden, et al. 1998. Cell-to-cell signaling and *Pseudomonas aeruginosa* infections. *Emerging Infectious Diseases*, 4(4):551-560
	36	Wagner, et al. 1987. Protein structures in solution by nuclear magnetic resonance and distance geometry: The polypeptide fold of the basic pancreatic trypsin inhibitor determined using two different algorithms, DISGEO and DISMAN. *J. Mol. Biol.*, 196:611-639
	37	Wlodawer, et al. 1993. Structure-based inhibitors of HIV-1 protease. *Annu. Rev. Biochem.*, 62:543-585
	38	Wuthrich, et al. 1983. Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance. *J. Mol. Biol.*, 169:949-961
	39	Xia, et al. 1999. Rapid method for the identification of essential genes in *Staphylococcus aureus*. *Plasmid*, 42:144-149

S:\DOCS\DOH\DOH-6639.DOC\dmb
043002

EXAMINER *Audm Mawsch*	DATE CONSIDERED 12-20-02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT